Citicoline is a mononucleotide composed of ribose, cytosine, pyrophosphate, and choline. It is an essential intermediate in the biosynthesis of phosphatidylcholine, a key component of neuronal membranes. In the Indian context, it is widely prescribed as a neuroprotective and neuroregenerative agent for acute and chronic cerebrovascular disorders, traumatic brain injuries, and cognitive deficits. It enhances cerebral metabolism, increases levels of neurotransmitters, and stabilizes cell membranes.
Adult: Oral: 500mg to 2000mg per day in 1-2 divided doses. Parenteral (IM/IV): 500mg to 1000mg per day. For acute stroke, higher doses (1000mg IV twice daily for 6 weeks) are used in protocols. The 250mg/ml strength allows for flexible dosing (e.g., 2ml = 500mg).
Note: Oral Solution: Can be taken with or without food. Parenteral: For IM injection, administer deep into a large muscle mass. For IV use, can be diluted in 50-100 mL of normal saline or 5% dextrose and infused over 30-45 minutes. Do not mix with other medications in the same syringe or infusion bag.
Citicoline exerts its effects through a multi-modal mechanism: 1) It provides choline and cytidine, which are rate-limiting precursors for the synthesis of phosphatidylcholine (a major phospholipid in neuronal membranes), thereby aiding in membrane repair and integrity. 2) It increases the synthesis of acetylcholine, a critical neurotransmitter for memory and cognition. 3) It attenuates the formation of free fatty acids and reactive oxygen species during ischemia, reducing neuronal apoptosis. 4) It restores the activity of mitochondrial ATPase and membrane Na+/K+ ATPase, improving cellular energy metabolism.
Pregnancy: Category B: Animal reproduction studies have not shown fetal risk, but no adequate, well-controlled studies in pregnant women. Use only if clearly needed and potential benefit justifies potential risk to the fetus.
Driving: Citicoline is not known to impair the ability to drive or use machines. However, if dizziness or hypotension occurs, patients should be cautioned.
| Levodopa/Carbidopa | Citicoline may potentiate the therapeutic effects of Levodopa in Parkinson's disease, possibly allowing for dose reduction. Monitor for dyskinesias. | Moderate |
| Cholinergic agents (e.g., Donepezil, Rivastigmine) | Additive cholinergic effects. May increase efficacy but also side effects like bradycardia, diarrhea, and nausea. | Moderate |
| Anticholinergic agents (e.g., Atropine, Trihexyphenidyl) | Theoretical antagonism of Citicoline's cholinergic effects. May reduce therapeutic efficacy. | Mild |
| Antihypertensives | Additive hypotensive effect, especially with IV administration. Monitor blood pressure. | Moderate |
| Mecobalamin | Often co-prescribed in neuropathic conditions; synergistic neuro-regenerative effect with no known adverse interaction. | None |